Levosimendan in Acute Kidney Injury Study

Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury

We hypothesise that levosimendan will have a positive influence on renal function during acute kidney injury in adult intensive care patients.

The purpose of this trial is to evaluate whether the use of levosimendan is able to improve renal function.

Inclusion Criteria:

• Clinically diagnosed adult patients with AKI

Exclusion Criteria:

• Failure to obtain written consent to participate from patient or legal representative (by deferred consent)
• Patients entering the ICU for post-operative observation with an estimated length of stay less than 24 hrs.
• Moribund patients
• Patients under the age of 18
• Pregnancy
• Patients suffering from pre-existing renal failure (elevated NGAL values without apparent rise in creatinine values)
• Renal replacement therapy initiated before admission due to Chronic Kidney Disease
• Hypersensitivity to levosimendan experienced by previous treatments
• Severe hypotension and tachycardia
• Significant mechanical obstruction affecting ventricular filling or outflow or both.
• Severe hepatic impairment (ALAT/ASAT>400U/L)
• Patients will be excluded if the treating physician judges that study participation is undesirable for medical, medical-ethical or other reasons
• Known history of Torsades de Pointes